Newsfeeds - Spark Newswire

2 minute read

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

Today, 10:49 PM

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.

AXSM

1 minute read

Axsome Therapeutics Announced FDA Approval of AUVELITY for the Treatment of Major Depressive Disorder in Adults

By Charles Gross

Today, 10:49 PM

Axsome Therapeutics, Inc. (NASDAQ: AXSM) today announced that the U.S.

AXSM

1 minute read

Analyst Ratings

What 4 Analyst Ratings Have To Say About Axsome Therapeutics

By Benzinga Insights

Today, 10:49 PM

Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings within the last quarter:

AXSM

1 minute read

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $55

By Benzinga Newsdesk

Today, 10:49 PM

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $54 to $55.

AXSM

22 minute read

Earnings Scheduled For August 9, 2022

By Benzinga Insights

Today, 10:49 PM

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

AAIC

4 minute read

Biotech Investors: August’s Key PDUFA Catalysts You Must Know

By Shanthi Rexaline

Today, 10:49 PM

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.

ACAD

1 minute read

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $54

By Benzinga Newsdesk

Today, 10:49 PM

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $27 to $54.

AXSM

1 minute read

What SVB Says On Axsome’s Strategy Review On Sunosi For Sleeping Disorder

By Vandana Singh

Today, 10:49 PM

Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed.

AXSM